A cute ischemic stroke is one of the major sources of morbidity and mortality in the industrialized countries. The lifetime risk of stroke is estimated to be 1 in 5 for middle-aged women and 1 in 6 for men according to the Framingham Study. 1 Outcome depends on the length of time between onset of symptoms and revascularization, the recanalization rate, and on whether or not intracranial hemorrhage occurs. 2 A meta-analysis of 52 studies on thrombolysis outcome in 2066 patients showed that the chance of an independent life after stroke increases 4.4 times for patients with successful recanalization compared with patients without recanalization; mortality rate decreases 4-fold. 2
cute ischemic stroke is one of the major sources of morbidity and mortality in the industrialized countries. The lifetime risk of stroke is estimated to be 1 in 5 for middle-aged women and 1 in 6 for men according to the Framingham Study. 1 Outcome depends on the length of time between onset of symptoms and revascularization, the recanalization rate, and on whether or not intracranial hemorrhage occurs. 2 A meta-analysis of 52 studies on thrombolysis outcome in 2066 patients showed that the chance of an independent life after stroke increases 4.4 times for patients with successful recanalization compared with patients without recanalization; mortality rate decreases 4-fold. 2 Intravenously administered tissue plasminogen activator (IV tPA) and local intra-arterial thrombolysis (IAT) have both been shown to improve patient outcome. However, the time window for treatment and the recanalization rate of both approaches are limited, [3] [4] [5] and the application of thrombolytic drugs increases the risk of symptomatic intracranial hemorrhage (sICH). 6 The success of recanalization, furthermore, depends on the occlusion site; proximal occlusions of large vessels such as the internal carotid artery have a poor recanalization rate after either IV tPA or IAT. 4, 5 Recent studies have examined whether mechanical recanalization techniques can accelerate the process of recanalization, increase the recanalization rate, and even expand the window of opportunity.
This article describes the evolution of the different mechanical thrombolysis and stenting techniques and their working principles for endovascular vessel recanalization and reviews the data on the outcome after acute stroke treatment.
Mechanical Thrombolysis
The various techniques and approaches for mechanical thrombolysis (MT) can be divided into 3 categories: thrombus disruption, immediate flow restoration with selfexpandable stents, and thrombectomy.
Thrombus Disruption
According to Pro-Urokinase for Acute Cerebral Thromboembolism-2 (PROACT II), IAT consists of local application of the fibrinolytic drug at the proximal surface of the thrombus. Mechanical clot disruption was not allowed according to the study protocol. 7 Various techniques for thrombus fragmentation have been advocated. The most common is probing the thrombus with the microwire and/or advancing the microcatheter into or beyond the thrombus. 8, 9 This simple mechanical procedure during IAT has been shown to improve the rate of successful recanalization (here defined as Thrombolysis in Myocardial Infarction score Ն2 10 or Thrombolysis in Cerebral Infarction score Ն2b 11 ). In middle cerebral artery occlusions, successful recanalization has reported in 79% 12 compared with the PROACT II data showing a recanalization rate of 66%. 13 Various studies have shown the efficacy of percutaneous balloon angioplasty at increasing the thrombus surface and achieving recanalization. 14, 15 The largest study compared 34 patients with M1 occlusions receiving percutaneous balloon angioplasty as the first-line treatment 15 to 36 patients treated with IAT alone (mean National Institutes of Health Stroke Scale [NIHSS], 16). Sufficient recanalization was achieved in 91.2% (versus 63.9%) with a favorable clinical outcome (here defined as modified Rankin Scale at 90-day follow-up Յ2) in 73.5% versus 50%, respectively. After percutaneous balloon angioplasty, however, 64.5% of patients required additional IAT to resolve distal emboli that occurred during treatment.
A modification of this technique is percutaneous balloon angioplasty using low-pressure remodeling balloons. A recent study reports on the use of this technique in conjunction with low-dose eptifibatide and/or IAT. 16 Treatment of 12 consecutive patients (mean NIHSS, 17) produced successful recanalization in 91.6% and a favorable clinical outcome in 41.6%.
Due to the risk of periprocedural complications and distal emboli associated with percutaneous balloon angioplasty, this technique has not emerged as a first-line technique and is reserved rather for patients in whom more conservative methods have failed.
More sophisticated intraluminal clot disruption devices apply ultrasound or laser technology. The EKOS system (EKOS, Bothell, WA) uses a 2.5-Fr microcatheter (MicroLysUS infusion catheter) with a 2.1-MHz piezoelectric sonography element at its distal tip. Local application of ultrasonic vibrations is intended to increase fluid permeation within the thrombus so as to enhance the effect of IAT. The initial clinical study on 14 patients with anterior and posterior circulation strokes (mean NIHSS, 18) showed a successful recanalization in 57% with a favorable clinical outcome in 43% of patients. 17 The rate of sICH was increased to 14% (compared with the 10% rate in PROACT II). The device has subsequently been investigated in the Interventional Management of Stroke (IMS)-II trial in which its application in 34 patients resulted in a recanalization rate of 73%. 18 Currently, the EKOS system is one of the 3 mechanical approaches being used in the IMS-III trial. 19 Laser-based technology is used by the EPAR system (EPAR; Endovasix, Belmont, CA), which aims to emulsify the clot by the application of microcavitation bubbles at the tip of the microcatheter. The clinical study enrolled 34 patients (mean NIHSS, 19) with occlusion sites in the anterior and posterior circulation. 20 In 18 of the 34 patients (53%), the device could be applied as intended with a recanalization rate of 61.1% in this subgroup. The study documented 1 severe adverse event (vessel rupture) and 5.9% of sICH with an overall mortality rate of 38.2%.
Approaches requiring adjuvant thrombolysis are prone to increase the rate of sICH, which is a potential disadvantage compared with techniques applying MT alone.
Stenting
Stent placement promises immediate flow restoration without repetitive passing and retrieval attempts and may render unnecessary the application of thrombolytic drugs. Instead of mechanical retrieval, intracranial stenting achieves recanalization by compressing the thrombus to the vessel wall and avoids the risk of proximal thrombus dislocation. However, intracranial stent placement in general, but especially in the setting of acute stroke, has some disadvantages. The compressed thrombus is likely to cause permanent side branch and perforator occlusion. Furthermore, the implant can cause short-term complications such as in-stent thrombosis and reocclusion of the vessel, requiring antiplatelet aggregation medication. However, this preventive medication regime might increase the risk of sICH in the stroke population. 21 Furthermore, the up to 32% restenosis rate reported for bare metal stents at intracranial stenosis in a 9-month follow-up period is matter for concern. 22 Different stent designs have been successfully applied to the clinical setting of acute stroke; self-expendable stents (SESs) are preferentially used over balloon-mounted stents. Preliminary data on the use of SES in the treatment of acute intracranial vessel occlusion is limited to case reports and small case series.
Levy et al 23 reported successful recanalization in 79% in 18 patients (mean NIHSS, 18) who presented with acute stroke. The placement of SES in the study, however, was accompanied by various other endovascular techniques. Moderate clinical outcome (here defined as modified Rankin Scale at 90-day follow-up Յ3) was achieved in 33.3%.
Brekenfeld et al 24 treated 12 patients (mean NIHSS, 14) with acute ischemic stroke using SES; IAT and/or mechanical thrombolysis failed in 7 patients before stent deployment. Successful recanalization was achieved in 92% of cases; moderate clinical outcome was reported in 50%; no sICH occurred.
Similarly, Linfante et al 25 reported on the use of SES in 19 patients with stroke (mean NIHSS, 19) as a rescue therapy after failure of arterial thrombolysis and/or mechanical thrombectomy. Successful recanalization was achieved in 95% of occlusions. Favorable clinical outcome was achieved in 42%. No intraprocedural complications were encountered; sICH occurred in 16%.
The Stent-Assisted Recanalization in Acute Ischemic Stroke (SARIS) trial is the first Food and Drug Administration-approved prospective trial investigating stenting for the treatment of acute stroke. It reports on 20 patients with stroke (mean NIHSS, 14) treated within the 6-hour window. In all cases (100%), the target vessel was recanalized after treatment. Adjuvant therapies including angioplasty, IAT, and IV tPA were applied in 63.2%. At 1-month and 6-month moderate clinical outcome was achieved in 60% of patients. 26, 27 Although the recanalization rate in all studies on the application of SES in patients with stroke is generally very high, it is debatable whether stenting in acute ischemic stroke has a future role as a first-line treatment due to the risks associated with intracranial stent placement and the recent success of thrombectomy. Stenting does, however, have clear value in selected cases of rescue therapy.
Mechanical Thrombectomy
All mechanical thrombectomy devices are delivered by endovascular access proximal to the occlusion site. The various devices can be divided into 3 major groups according to where they apply force on the thrombus.
Proximal devices apply force to the proximal base of the thrombus; this group includes various aspiration catheters and systems.
Distal devices approach the thrombus proximally but then are advanced by a microcatheter past the thrombus to be unsheathed behind it, where force is applied to the distal base of the thrombus; this group includes brush-like, basket-like, or coil-like devices.
The most recently developed devices include stent-like devices that are placed across the occlusion side, deployed within the thrombus, and then retrieved; this group includes various self-expandable stent retrievers (SRs).
Thrombus Aspiration and Proximal Thrombectomy
The first reports on mechanical thrombectomy in acute stroke treatment included the use of aspiration catheters. 28, 29 A large microcatheter (4 -5 Fr) is advanced to the proximal surface of the clot and suction force is applied using a 60-mL syringe. Entrapment of the thrombus is indicated by the absence of backflow. The catheter is then retrieved with constant negative pressure to avoid loss of thrombus. After each retrieval of clot fragments, the procedure is repeated.
Although widely applied, few data have been published on this approach so far. A recent single-center study reported on 22 consecutive patients (mean NIHSS, 18) treated with aspiration thrombectomy alone. Sufficient recanalization was achieved in 81.9% and a favorable clinical outcome in 45.5%. 30 The method is technically simple, fast to apply, and inexpensive. It is widely used, especially in proximal occlusions (eg, distal cervical internal carotid artery, internal carotid artery terminus) when the target vessel has a large diameter and an anatomy favorable for device navigation.
Penumbra System
The Penumbra system (Penumbra, Alameda, CA) is a refinement of the proximal thrombectomy technique. It applies continuous aspiration in conjunction with mechanical fragmentation and was approved by the Food and Drug Administration for clot removal in stroke treatment in 2007.
Reperfusion catheters of various sizes (0.26 -0.51 inch) are advanced to the proximal surface of the thrombus and connected to an aspiration pump providing continuous aspiration (Ϫ700 mm Hg). To avoid the obstruction of the aspiration catheter, additional clot fragmentation is achieved with a teardrop-shaped separator mounted at the distal end of the microwire (Figure 1 ). This setting allows cleaning of the catheter tip of clot fragments at the same time as keeping the device in place during recanalization. The aim of this setting is to debulk the clot from proximal to distal; small catheter sizes should facilitate thrombectomy even in distal branches such as M2 segments.
The Penumbra system has been investigated in numerous single-center and multicenter trials. The Penumbra Pivotal Stroke Trial prospectively examined the results in 125 stroke patients (mean NIHSS, 18) within a window of 8 hours after onset of symptoms. Recanalization of the target vessel was achieved in 81.6%. The study did not state the percentage of patients that received IV tPA before mechanical recanalization. Despite the convincing recanalization rate, clinical outcome was poor; favorable clinical outcome was achieved in only 25% of all patients and in 29% of patients with successful recanalization. The rate of sICH was 11.2% and overall mortality was 32.8%. 31 Serious adverse events occurred in 3.2% of cases.
The high recanalization rate in correlation to the poor clinical results in this trial sparked the discussion on the value of recanalization using MT. However, some single-center studies reported better clinical results with the Penumbra system than those of the Pivotal Trial. Kulcsar et al 32 reported on a series of 27 patients (mean NIHSS, 14) with large vessel occlusions. The mean procedural time was rather long (1.6 hours). Successful recanalization was achieved in 93% of patients, favorable clinical outcome was found in 48%, and all-cause mortality was reduced to 11%.
The Penumbra system is one of the devices currently being investigated in the IMS-III trial. 19 
Distal Thrombectomy
Due to the technical disadvantages associated with largediameter aspiration catheters as well as the low retrieval rate of aspiration, a novel generation of distal thrombectomy devices was developed. The microcatheter (0.18 -0.27 inch) for the deployment of distal devices is usually easy to navigate even in tortuous vessel anatomy to the intracranial occlusion side. After passing the clot, the device is deployed distally to the thrombus. This approach shifts the application of force to the distal base of the thrombus, which has been shown to increase the efficacy of thrombectomy in vivo. However, vasospasm and vessel wall damage have been more frequently described in association with distal devices. Furthermore, during retrieval, the loose engagement of the clot with the distal device is prone to cause thromboembolic events. For most distal devices, therefore, proximal balloon occlusion and aspiration from the guide catheter (flow reversal) during retrieval are recommended.
Various distal devices have been advocated in the past (eg, Phenox, Bochum, Germany; Catch, Balt, Montmorency, France), most of them available in Europe only. Large clinical experience has been reported on the Merci devices, the first device of this group to receive Food and Drug Administration approval (in 2004).
Merci Devices
The essential component of the Merci Retrieval System (Concentric Medical, Mountain View, CA) is the Merci retriever (Figure 2) . The initial Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial evaluated the safety and efficacy of the Merci system in the setting of acute stroke within 8 hours of onset in 151 patients (mean NIHSS, 20) who were ineligible for IAT. 33 The trial included patients with anterior circulation (90%) and posterior circulation (10%) stroke. Successful recanalization was achieved in 46% of the treated patients, significantly higher compared with the control group, the spontaneous recanalization rate of 18% of the PROACT II trial. 7 Favorable clinical outcome was achieved in 27.7% of patients. The mean procedure duration was 2.1 hours; clinically significant procedural complications occurred in 7.1% of patients; the sICH rate was 7.8%.
The Multi-MERCI trial was an international, single-arm trial that investigated 164 patients (mean NIHSS, 19) within an 8-hour window after symptom onset. 34 The primary end point was target vessel recanalization. In contrast to the MERCI trial, prior treatment with IV tPA, IAT, or other mechanical techniques was allowed and new generations of the Merci device were included. Successful recanalization was achieved in 57.3% using the retriever alone and in 69.5% in conjunction with other treatment modalities. A favorable clinical outcome was achieved in 36% of patients. Mean procedure duration was 1.6 hours and therefore again remarkably long for a mechanical approach. Clinically significant procedural complications occurred in 5.5% of patients; the sICH rate was 9.8%.
The introduction of the device was a landmark of mechanical recanalization in stroke treatment. Both MERCI trials demonstrated a significantly better clinical outcome in patients with successful recanalization. The group of Merci devices is currently being assessed within the IMS-III trial. 19 
Stent Retriever
The most recently introduced mechanical devices for acute stroke treatment are self-expandable, stent-like thrombectomy devices. Combining the advantages of temporary stenting with immediate flow restoration without the need for permanent implantation plus thrombectomy with definitive thrombus removal, SR devices offer a promising new treatment option for acute ischemic stroke. The devices are applied in a manner comparable to that of intracranial stents. After passing the occlusion site with a microcatheter (0.21-0.27-inch inner diameter), the SR -is deployed covering the entire thrombus. The radial force of the SR can immediately generate a channel compressing the thrombus and restore flow to the distal territory. Adjuvant IAT can be applied at this point. After an embedding time of 3 to 10 minutes, the deployed stent is slowly retrieved. As for distal devices, proximal balloon occlusion and flow reversal by aspiration at the guide catheter during retrieval is recommended.
Numerous variants of this device type are currently under development or in first clinical trials (TREVO, Concentric Medical, Mountain View, CA; PULSE, Penumbra, Alameda, CA; ReVive, Micrus, CA).
The first dedicated combined flow restoration and thrombectomy device for acute stroke treatment was the Solitaire FR (ev3, Irvine, CA; Figure 3) . The device is a modification of the Solitaire AB Neurovascular Remodeling Device, originally developed for stent-assisted treatment of wide-neck intracranial aneurysms. Within a short period of time, numerous studies have reported on the in vivo and clinical application of the Solitaire FR for stroke treatment.
Castano et al 35 reported in 2010 on their initial experience in 20 patients with acute stroke within an 8-hour time window. Successful recanalization was achieved in 90% of cases with a mean procedural time of 50 minutes. A favorable clinical outcome was attained in 45%; the sICH rate was 10%. Other small case series using SR have shown similar successful recanalization rates (88%-91%) and fast procedural times (42-55 minutes) with comparable rates of favorable clinical outcome (42%-54%). 36 -38 
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The largest study to date summarizes these findings. The retrospective collection of cases from 6 large European stroke centers reports on outcome in 141 patients with acute patients (mean NIHSS, 18) treated for occlusions in the anterior (internal carotid artery: 27%, middle cerebral artery: 59%) and posterior circulation (14%). Mean recanalization time was 45 minutes; Thrombolysis in Cerebral Infarction Ն2b was achieved in 86% of target vessels. A favorable clinical outcome was found in 55% of patients. Overall mortality was 20.5%. 39 The results of 2 larger trials are expected. The SWIFT trial (Solitaire FR with the Intention for Thrombectomy) is a randomized trial comparing the efficacy and safety of the Solitaire FR system with that of the Merci device. Patients included in the trial may be ineligible for or have failed IV tPA within an 8-hour window. The primary outcome is recanalization of an occluded target vessel to Thrombolysis in Myocardial Infarction Ն2. Secondary outcomes are recanalization time and modified Rankin Scale at 90-day follow-up. The SWIFT study was halted by the data monitoring board early in 2011 after 126 patients of the anticipated 250 had been enrolled. The results have not been published yet but favorable results for Solitaire FR can be assumed.
The Solitaire FR is currently being evaluated in the STAR Trial (Solitaire FR Thrombectomy for Acute Revascularization). This prospective, international single-arm study has an enrolment goal of 200 consecutive patients with anterior circulation occlusion treated within a window of 8 hours. The study includes patients ineligible for or with failed IV tPA after bridging therapy or thrombectomy as initial treatment. The primary outcomes are recanalization rate of the target vessel to Thrombolysis in Cerebral Infarction Ն2b and safety. Secondary outcomes are recanalization time and modified Rankin Scale at 90-day follow-up. First results can be expected mid-2012.
The promising advances in SR compared with previous MT approaches are its reported high recanalization rate and marked reduction in recanalization time. Furthermore, it appears that the high recanalization rate ultimately correlates with a marked elevation in the rate of favorable clinical outcomes.
Discussion
Rapid restoration of cerebral blood flow is the principle goal of ischemic stroke therapy and is associated with better clinical outcome and reduced mortality rate after acute stroke. MT is performed using a variety of endovascular recanalization techniques, which have undergone rapid evolution in recent years. Nevertheless, current endovascular stroke treatment remains a multimodal approach combining the advantages of different MT techniques often in conjunction with IAT. Concerning the severity of intracranial complications, endovascular recanalization techniques should be reserved to dedicated stroke centers.
The introduction of mechanical approaches has undoubtedly expanded the time window for stroke treatment and broadened the treatment to patients in whom IV tPA or IAT failed or is contraindicated. The future role and true clinical value of MT is hard to predict and even difficult to investigate. The latest results indicate that MT can achieve high recanalization rates in conjunction with short recanalization times and a low-risk device-related severe adverse event.
More importantly, recent data show that the increased recanalization rate of MT improves clinical outcome.
Considering the poor recanalization rate and clinical outcome of patients with proximal vessel occlusions and large thrombus burden (eg, tandem occlusions and internal carotid artery termination), MT is likely to become a first-line treatment. On the other hand, due to the delicate intracranial anatomy and the convincing results of IV tPA in peripheral and M2 occlusions, MT is unlikely to expand into this territory.
More large multicenter series are necessary to elucidate the clinical role of MT in the majority of patients with stroke with proximal middle cerebral artery and basilar artery occlusions. Although likely to influence the clinical outcome of the patient after endovascular stroke treatment, to date no commonly accepted peri interventional protocol exists. Therefore, the use of proximal protection in case of thrombectomy, the application of local anaesthesia versus general anaesthesia as well as additional use of thrombolytic drugs during MT is up to the center's preferences. Some relevant results will be available soon and to define the peri interventional protocol (eg, IMS III, SWIFT, and STAR). Unfortunately, due the rapid rate of evolution, the multimodal approach as well as the many different devices introduced to date, any randomized study will be difficult to conduct and is prone to remain incomplete.
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